Company profile: Tonix Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pharmaceutical products focused on central nervous system disorders, including TNX-102 SL sublingual tablet for fibromyalgia, Long COVID and acute stress disorder; TNX-1500 anti-CD40L antibody for transplant rejection and autoimmune conditions; TNX-801 live horsepox vaccine for smallpox/monkeypox; TNX-2900 intranasal oxytocin for Prader-Willi syndrome; TNX-1700 for gastric/colorectal cancers; and TNX-1300 for cocaine overdose.
Products and services
- TNX-1300: A Breakthrough Therapy-designated biologic in mid-Phase II for treating cocaine intoxication/overdose, focused on acute care of toxic exposure cases
- TNX-102 SL: A sublingual tablet for managing fibromyalgia, also in development for treating Long COVID and acute stress disorder
- TNX-2900: An intranasal oxytocin for treating Prader-Willi syndrome, granted FDA Orphan Drug and Rare Pediatric Disease designations, configured for nasal administration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tonix Pharmaceuticals
Openwater
HQ: United States
Website
- Description: Provider of a medical technology system focused on treating diseases at the cellular level.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Openwater company profile →
CuraSen Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurodegenerative diseases, developing orphan drugs including CST-103/CST-107, a combination therapy targeting cognitive symptoms and disease progression in Parkinson’s disease (Phase 2); CST-2032/CST-107 for Alzheimer’s disease with similar focus (Phase 2); and CST-3056, an alpha-1A adrenoceptor agonist in preclinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CuraSen Therapeutics company profile →
NeuroReality
HQ: The Netherlands
Website
- Description: Provider of VR-based cognitive rehabilitation and brain training solutions using neuroscience and gamification. Offers Koji's Quest, a patient-centric SaaS VR game for recovery from brain injuries, connecting clinicians and patients to improve outcomes and enable superior care. Organizes clinical trials to evaluate effectiveness and prepares Koji's Quest for individual self-training via the Oculus Quest store.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroReality company profile →
Prexton Therapeutics
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical drug development focused on innovative drugs to improve quality of life. Swiss-based, founded in 2012 by Francois Conquet and MS Ventures under the Merck Serono Entrepreneur Partnership Program, applying a new scientific approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prexton Therapeutics company profile →
Anaconda Biomed
HQ: Spain
Website
- Description: Provider of next-generation catheter-based medical devices for efficient mechanical thrombectomy, developing the ANCD BRAIN, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anaconda Biomed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tonix Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tonix Pharmaceuticals
2.2 - Growth funds investing in similar companies to Tonix Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tonix Pharmaceuticals
4.2 - Public trading comparable groups for Tonix Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →